Oncolytics Biotech Inc. Announces Issuance of 33rd U.S. Patent
29-Oct-2009
- Canada
"This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN(R) in combination with a range of chemotherapeutic agents," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.